Breaking News Instant updates and real-time market news.

AGN

Allergan

$174.85

0.18 (0.10%)

, AZN

AstraZeneca

$43.92

0.22 (0.50%)

04:55
10/23/19
10/23
04:55
10/23/19
04:55

America College of Chest Physicians to hold annual meeting

CHEST Annual Meeting 2019 will be held in New Orleans on October 19-23.

AGN

Allergan

$174.85

0.18 (0.10%)

AZN

AstraZeneca

$43.92

0.22 (0.50%)

BAYRY

Bayer

$0.00

(0.00%)

BLPH

Bellerophon

$0.57

0.0636 (12.66%)

ELMD

Electromed

$6.97

0.13 (1.90%)

GLPG

Galapagos

$155.00

-2.84 (-1.80%)

GSK

GlaxoSmithKline

$42.51

-0.09 (-0.21%)

INSM

Insmed

$18.24

(0.00%)

INSP

Inspire Medical

$54.78

-1.715 (-3.04%)

ISRG

Intuitive Surgical

$535.91

-26.675 (-4.74%)

JAZZ

Jazz Pharmaceuticals

$122.57

1.59 (1.31%)

LIVN

LivaNova

$72.45

-2.845 (-3.78%)

REGN

Regeneron

$301.81

3.95 (1.33%)

RCKT

Rocket Pharmaceuticals

$14.11

0.48 (3.52%)

PRTK

Paratek Pharmaceuticals

$3.51

0.31 (9.69%)

OCX

OncoCyte

$1.62

-0.045 (-2.70%)

NVS

Novartis

$86.83

0.28 (0.32%)

NUAN

Nuance

$15.44

-0.21 (-1.34%)

MYL

Mylan

$18.31

0.16 (0.88%)

MRK

Merck

$81.30

-3.24 (-3.83%)

MNK

Mallinckrodt

$2.86

0.32 (12.60%)

MLNT

Melinta Therapeutics

$4.84

0.265 (5.80%)

MDT

Medtronic

$104.52

-2.11 (-1.98%)

LJPC

La Jolla

$8.41

-0.24 (-2.77%)

SIEGY

Siemens

$0.00

(0.00%)

SNY

Sanofi

$45.31

-0.64 (-1.39%)

TAK

Takeda Pharmaceutical

$17.55

0.03 (0.17%)

UTHR

United Therapeutics

$84.18

0.13 (0.15%)

VCYT

Veracyte

$26.17

-0.01 (-0.04%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 12

    Nov

  • 14

    Nov

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

  • 07

    Dec

  • 12

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

AGN Allergan
$174.85

0.18 (0.10%)

09/12/19
UBSW
09/12/19
NO CHANGE
Target $189
UBSW
Buy
Allergan price target raised to $189 from $172 at UBS
UBS analyst Navin Jacob, who this morning upgraded AbbVie (ABBV) to Buy from Neutral, raised his price target on Allergan (AGN) shares to $189 from $172 based on the two companies' deal terms and his revised AbbVie price target of $79. He expects the AbbVie deal to close in the first quarter of 2020, stating that he believes the two have sufficiently addressed possible anti-trust issues with the divestitures of Zenpep and Creon. Jacob keeps a Buy rating on Allergan shares.
09/24/19
ADAM
09/24/19
NO CHANGE
Target $13
ADAM
Buy
Sientra valuation offers compelling risk/reward, says Canaccord
Canaccord analyst Kyle Rose believes the current valuation of Sientra (SIEN) offers a compelling risk/reward as the set up into Q3 and Q4 appears to be positive. The analyst believes its improving inventory position and major recall from market leader Allergan (AGN) should serve to accelerate the share taking opportunity in the breast implant market. Rose reiterated his Buy rating and $13 price target on Sientra shares.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
09/30/19
WELS
09/30/19
NO CHANGE
Target $184
WELS
Outperform
Allergan price target raised to $184 from $176 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Allergan (AGN) to $184 from $176 as the company is in the process of being acquired by AbbVie (ABBV) and to account for the change in the latter's stock price from the proposed deal. Despite the FTC's second request, he does not believe there is a significant risk of the deal not being finalized given the little overlap there is between the companies. The analyst reiterates an Outperform rating on Allergan's shares as he likes standalone Allergan shares, and believes the current deal spread is attractive.
AZN AstraZeneca
$43.92

0.22 (0.50%)

08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
BAYRY Bayer
$0.00

(0.00%)

07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
10/21/19
PIPR
10/21/19
NO CHANGE
Target $100
PIPR
Overweight
Piper reiterates Overweight on Crispr Therapeutics with $100 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics (CRSP) with a $100 price target after the company announced the consolidation of the Casebia joint venture with Bayer (BAYRY). Casebia will now operate within Crispr to develop its hemophilia, ophthalmology and autoimmune programs, Tenthoff tells investors in a research note. The primary driver for shares remains first ever CTX001 data in beta thalassemia and sickle cell disease in December, says Tenthoff.
BLPH Bellerophon
$0.57

0.0636 (12.66%)

01/24/19
MAXM
01/24/19
INITIATION
MAXM
Buy
Bellerophon initiated with a Buy at Maxim
01/24/19
MAXM
01/24/19
INITIATION
Target $3
MAXM
Buy
Bellerophon initiated with a Buy at Maxim
Maxim analyst Caroline Palomeque initiated Bellerophon with a Buy rating and a price target of $3, saying the company's lead product INOpulse is well positioned in the absence of other "FDA-approved treatment options for pulmonary hypertension associated with Interstitial Lung Disease". The analyst notes that shares were down significantly in Q3 of 2018 after the company's phase 3 study in pulmonary arterial hypertension was stopped for futility, but she sees upside from the program's intact clinical path forward and expectations of more data later this year.
ELMD Electromed
$6.97

0.13 (1.90%)

10/18/19
DOTC
10/18/19
INITIATION
Target $12
DOTC
Buy
Electromed initiated with a Buy at Dougherty
Dougherty analyst Kyle Bauser initiated coverage of Electromed with a Buy rating and $12 price target.
GLPG Galapagos
$155.00

-2.84 (-1.80%)

07/29/19
RBCM
07/29/19
NO CHANGE
Target $171
RBCM
Sector Perform
Galapagos price target raised to $171 from $132 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Galapagos (GLPG) to $171, saying the company is in a "comfortable position" after its "lucrative" Gilead (GILD) deal and the elevation of Filgotinib to commercial status possibly coming next year. The analyst cites the FDA's greater permissiveness on filing and the company's latest comments on Filgotinib safety, though he also intends to monitor the "competitive dynamics" to gauge the program's long-term potential.
07/31/19
UBSW
07/31/19
UPGRADE
UBSW
Buy
Galapagos upgraded to Buy from Neutral at UBS
09/09/19
MSCO
09/09/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos with an Overweight rating and $200 price target.
09/10/19
MSCO
09/10/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos (GLPG) with an Overweight rating and $200 price target. The analyst believes Galapagos is well positioned for success following the transaction with Gilead (GILD). He believes Gilead offers a "strong partner" to drive the company's "broad" pipeline while building commercial operations in Europe. Filgotinib will drive near-term upside in Galapagos shares while its greater than $5B cash position provides downside protection, Harrison tells investors in a research note.
GSK GlaxoSmithKline
$42.51

-0.09 (-0.21%)

09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
10/11/19
CANT
10/11/19
UPGRADE
CANT
Overweight
GlaxoSmithKline upgraded to Buy from Hold at Cantor Fitzgerald
Cantor Fitzgerald analyst Brian White upgraded GlaxoSmithKline to Buy from Hold with a price target of 2,000 pence.
10/11/19
CANT
10/11/19
UPGRADE
CANT
Overweight
Cantor upgrades GSK to Buy on reinvigoration of cancer franchise
Cantor Fitzgerald analyst Brian White upgraded GlaxoSmithKline to Buy from Hold with a price target of 2000 pence, up from 1450 pence. The Novartis transactions bolstered GSK's Vaccines and Consumer businesses at the expense of Pharma, while recent events have served to continue the theme while reinvigorating the cancer franchise, White tells investors in a research note. The analyst believes GSK has access to differentiated oncology products, "which promise to form a cornerstone for future franchise building." Further, consummation of the Consumer business should drive greater profitability "but Pharma has a narrow window to build a sustainable late stage pipeline," he adds.
10/16/19
NWST
10/16/19
UPGRADE
NWST
Neutral
GlaxoSmithKline upgraded to Hold from Reduce at New Street
INSM Insmed
$18.24

(0.00%)

03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
04/09/19
HCWC
04/09/19
NO CHANGE
Target $52
HCWC
Buy
Insmed price target raised to $52 from $43 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed to $52 from $43 saying the company yesterday announced a positive update on the U.S. launch of Arikayce. The broadening of the prescriber base "is not short lived and can continue, as well as possibly be supplemented by label expansion into first line patients," Fein tells investors in a research note. He keeps a Buy rating on the shares.
08/01/19
STFL
08/01/19
NO CHANGE
Target $43
STFL
Buy
Insmed selloff 'decidedly overdone,' says Stifel
Stifel analyst Adam Walsh notes that despite another "strong beat and raise quarter," Insmed's shares are trading off, which is likely attributable to persistent concerns regarding future Arikayce drop-outs leading to a flattening of the growth curve, some timing uncertainty on the front-line trial launch, and the recent capital raise done at $26/share and related selling pressure based on that alone. On drop-outs, the analyst acknowledges lack of long-term visibility but believes the rate thus far has been better than expected. On the PRO measure, Walsh believes it is "critically important" for Insmed to "get it right," given the large font-line opportunity. Overall, the analyst sees the selloff as "decidedly overdone" in light of the continued strong Arikayce launch execution and encouraging forward guidance. Walsh reiterates a Buy rating and $43 price target on the shares.
09/03/19
GSCO
09/03/19
INITIATION
Target $30
GSCO
Buy
Insmed initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh initiated Insmed with a Buy rating and a price target of $30, saying the stock offers an attractive entry point at 50% below its 52-week high as a de-risked commercial-stage biopharma with "significant" potential for expansion. The analyst contends that Insmed's lead orphan lung disease product Arikayce is well-positioned with it's early life cycle stage, no obvious competition and the potential for both geographic and label expansion. Suvannavejh adds that the company's INS1007 also has pipeline potential while garnering "little investor attention".
INSP Inspire Medical
$54.78

-1.715 (-3.04%)

11/28/18
BREN
11/28/18
INITIATION
Target $31
BREN
Sell
Inspire Medical initiated with a Sell at Berenberg
Berenberg initiated Inspire Medical with a Sell and $31 price target.
02/05/19
DOTC
02/05/19
INITIATION
Target $64
DOTC
Buy
Inspire Medical initiated with a Buy at Dougherty
Before the market open, Dougherty analyst Kyle Bauser initiated Inspire Medical with a Buy rating and $64 price target.
07/08/19
BOFA
07/08/19
NO CHANGE
Target $75
BOFA
Neutral
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.
09/27/19
DOTC
09/27/19
NO CHANGE
Target $78
DOTC
Buy
Inspire Medical received positive draft LCDs from two more MACs, says Dougherty
Dougherty analyst Kyle Bauser said that National Government Services and CGS Administrators issued positive draft policies for the Inspire therapy that were consistent with the previous draft local coverage determinations, or LCDs. He notes that, including those two, six Medicare Administrative Contractors, or MACs, have issued positive LCD drafts covering 44 states and said he expects the one remaining MAC to follow suit. Bauser reiterated a Buy rating and $78 price target on Inspire Medical shares.
ISRG Intuitive Surgical
$535.91

-26.675 (-4.74%)

09/25/19
PIPR
09/25/19
NO CHANGE
Target $633
PIPR
Overweight
Piper says Intuitive Surgical overhang over after Medtronic unveils Hugo
Medtronic (MDT) yesterday afternoon showcased its long-awaited multi-port surgical robot Hugo, which will compete with Intuitive Surgical's (ISRG) da Vinci, Piper Jaffray analyst Matt O'Brien tells investors in a research note. As expected, Medtronic's robot is a fully modular system with an open console design and 3D vision, says the analyst. He believes Hugo should garner interest from hospitals considering its value proposition. However, Medtronic's system is at least two years out from the U.S., and the company will not be giving the system away for free like some feared, explains O'Brien. Competition has been an overhang for Intuitive for the last several months, says O'Brien, who left yesterday "feeling A LOT better about Intuitive's competitive positioning and long term growth potential." He believes Intuitive Surgical's overhang is over and that the company is likely to remain the market leader. The analyst keeps an Overweight rating on the shares with a $633 price target. O'Brien also has an Overweight rating on Medtronic with a $120 price target.
09/25/19
GUGG
09/25/19
NO CHANGE
GUGG
Neutral
Medtronic financial projections for Hugo robot 'underwhelming,' says Guggenheim
After attending Medtronic's (MDT) "much-anticipated" robotic-assisted surgery event, where the company gave a first look at the Hugo RAS system, Guggenheim analyst Chris Pasquale noted that the company gave an update on regulatory timelines and initial revenue targets, though information on pricing and clinical comparability to Intuitive Surgical's (ISRG) da Vinci system were "notably absent." He was impressed by certain design elements, though he thinks management's financial projections for Hugo were "somewhat underwhelming," said Pasquale, who keeps a Neutral rating on Medtronic shares.
10/18/19
PIPR
10/18/19
NO CHANGE
Target $633
PIPR
Overweight
Intuitive Surgical Q3 'solid' despite light placements, says Piper Jaffray
Intuitive Surgical last night reported "solid" Q3 results with an "exceptional" margin profile and an acceleration in procedure growth at 20%, Piper Jaffray analyst JP McKim tells investors in a research note. However, system placements were a little light and SP commentary was disappointing as the market feedback from physicians is not tracking to the system placements and revenue at this time, adds the analyst. Nonetheless, McKim remains bullish on single port surgery and views it as the future for a lot of cases. He reiterates an Overweight rating on Intuitive Surgical with a $633 price target.
10/18/19
RAJA
10/18/19
NO CHANGE
Target $615
RAJA
Outperform
Intuitive Surgical price target raised to $615 from $610 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target for Intuitive Surgical to $615 from $610 and maintained an Outperform rating following the company's "strong" Q3 earnings report. In a research note to investors, Keusch says he remains constructive on shares, given a multi-year new product cycle, procedure growth trends remaining intact, and significant balance sheet optionality with a ~$5.4B in net cash position. The analyst says he is a buyer of the stock following the "robust" performance, and says he views near-term competitive concerns as now largely derisked in the mid-term.
JAZZ Jazz Pharmaceuticals
$122.57

1.59 (1.31%)

08/07/19
LEHM
08/07/19
NO CHANGE
Target $180
LEHM
Overweight
Jazz Pharmaceuticals price target raised to $180 from $164 at Barclays
Barclays analyst Balaji Prasad raised his price target for Jazz Pharmaceuticals to $180 from $164 saying Xyrem outperformed Q2 while Sunosi "looks promising" and the pipeline expands. The analyst has a "strong" outlook for Jazz's sleep franchise and keeps an Overweight rating on the shares.
08/21/19
PIPR
08/21/19
DOWNGRADE
Target $142
PIPR
Neutral
Jazz Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Jazz Pharmaceuticals to Neutral from Overweight after conducting a survey of 30 current prescribers of Xyrem in order to gauge whether there will be physician appetite for using recently approved Wakix, either in replacement or in combination. The overall level of enthusiasm for Wakix was high enough to cause him "meaningful concern" about the trajectory of Xyrem starting next year following the competing drug's launch, said Amsellem, who now questions if Jazz shares can see meaningful multiple expansion in the next 6-12 months. He lowered his price target on Jazz shares to $142 from $205.
08/21/19
08/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cree (CREE) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying the company has forecasted soft business conditions to persist into the quarter. 2. Hawaiian Holdings (HA) double downgraded to Sell from Buy at Stifel with analyst Joesph DeNardi citing 2020 earnings risk. 3. Chimera (CIM) downgraded to Neutral from Outperform at Credit Suisse with analyst Douglas Harter citing valuation. 4. Synlogic (SYBX) downgraded to Sell from Buy at Citi and to Perform from Outperform at Oppenheimer. 5. Jazz Pharmaceuticals (JAZZ) downgraded to Neutral from Overweight at Piper Jaffray with analyst David Amsellem citing his survey of 30 current prescribers of Xyrem in order to gauge whether there will be physician appetite for using recently approved Wakix, either in replacement or in combination. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
BERN
10/14/19
INITIATION
Target $150
BERN
Market Perform
Jazz Pharmaceuticals reinitiated with a Market Perform at Bernstein
Bernstein analyst Aaron Gal reinitiated Jazz Pharmaceuticals with a Market Perform rating and a $150 price target. The analyst continues to see it as a "solid company" but believes Jazz is facing several long-term risks, plus negative catalysts in the coming year:
LIVN LivaNova
$72.45

-2.845 (-3.78%)

06/05/19
PIPR
06/05/19
NO CHANGE
Target $90
PIPR
Overweight
Piper recommends looking at LivaNova despite possible 'messy' Q2
Piper Jaffray analyst Matt O'Brien, while acknowledging the company's Q2 "could again be messy," encourages investors to take a look at LivaNova shares. After reviewing Epidiolex scripts in Q2, the analyst found that uptake of the drug is still growing, though he adds the "curve is clearly flattening this quarter." The raw number of scripts filled suggests that the disruption seen at LivaNova may be more related to buzz around this cannabis product as opposed to vagus nerve stimulation candidates actually switching to Epidiolex, O'Brien tells investors in a research note. He expects LivaNova's Neuromod segment to rebound following a "disappointing" Q1 and keeps an Overweight rating on the company's shares with a $90 price target.
07/31/19
PIPR
07/31/19
NO CHANGE
PIPR
Overweight
LivaNova core visibility, TRD opportunity underappreciated, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said LivaNova's report of some stabilization in the Neuromod franchise was a key takeaway from the company's Q2 results. He maintains his view that the Neuromod franchise will rebound in the second half of the year and that TRD is receiving minimal value despite the fact that the first enrollment in the TRD trial is still on track for late this quarter, O'Brien tells investors. He keeps an Overweight rating on LivaNova shares.
09/06/19
PIPR
09/06/19
NO CHANGE
PIPR
Piper Jaffray says positive updates continue for LivaNova
Piper Jaffray analyst Matt O'Brien spoke to LivaNova's management following CMS approval the company's treatment-resistant depression, or TRD, protocol, and he views the updates positively and continues to see TRD as "one of the most exciting and large pipeline opportunities" for the company. O'Brien was also positive on the company's turnaround of its core Neuromod business due to its "solid" Q2 results, and maintained an Overweight rating and $90 price target on LivaNova shares.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $90
PIPR
Overweight
LivaNova first patient enrollment in RECOVER 'an important step,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien notes that LivaNova announced it had enrolled the first patient in its CMS approved RECOVER clinical study. Although the timing is in-line with management's expectations, there had been some concern that it would slip, he notes, adding that the announcement is "certainly positive" and "an important step" for the company's topline outlook. On the whole, the analyst believes the announcement serves as a starting point for eventual coverage. O'Brien reiterates an Overweight rating and $90 price target on the shares.
REGN Regeneron
$301.81

3.95 (1.33%)

10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/08/19
PIPR
10/08/19
NO CHANGE
Target $435
PIPR
Overweight
Piper positive on Regeneron after 'significant let-down' Novartis label
Piper Jaffray analyst Christopher Raymond is "incrementally positive" on Regeneron Pharmaceuticals (REGN) after the FDA approved Novartis' (NVS) Beovu for the treatment of wet age-related macular degeneration. While the approval was anticipated and physician anticipation of the drug has been high, doctors are likely to view the drug's label "as a significant let-down," Raymond tells investors in a research note. The analyst says that with inflammation and immunogenicity rates meaningfully higher than Regeneron's Eylea, and the lack of flexibility to dose more frequently, he sees little reason for doctors to switch. And while some investors may point to price as another meaningful lever, off-label Avastin makes for an "insurmountable bar for the price-sensitive segment," says Raymond. He keeps an Overweight rating on Regeneron shares with a $435 price target. The label "renders Beovu as little more than an also-ran," contends the analyst. As such, Raymond thinks Eylea's dominance in remains intact.
10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.
10/16/19
BOFA
10/16/19
INITIATION
Target $325
BOFA
Neutral
Regeneron reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Regeneron with a Neutral rating and $325 price target. The analyst sees declining Eylea revenues partially offset by the strong launch of Dupixent, and cited the overall "push/pull of multiple major value drivers" as the reason for his Neutral stance.
RCKT Rocket Pharmaceuticals
$14.11

0.48 (3.52%)

03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
BARD
04/22/19
INITIATION
Target $28
BARD
Outperform
Rocket Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar started Rocket Pharmaceuticals with an Outperform rating and $28 price target.
04/22/19
BARD
04/22/19
INITIATION
BARD
Outperform
Rocket Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Rocket Pharmaceuticals with an Outperform rating and a $28 price target, with the analyst saying that lentiviral gene therapy RP-L102 for the treatment of Fanconi anemia type A, which is currently in Phase 1/2 with data expected in the second half of the year, could serve as a "key catalyst" for the stock.
09/26/19
PIPR
09/26/19
INITIATION
Target $35
PIPR
Overweight
Rocket Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started Rocket Pharmaceuticals with an Overweight rating and $35 price target. The company's lentiviral-based pipeline is supported by "extensive" preclinical and early clinical data and could generate combined global peak sales exceeding $1B, Van Buren tells investors in a research note. Further, if ultimately successful, RP-A501 could surpass $3B in global sales by 2030, says the analyst. He attributes the recent share pullback to AAV9-related safety concerns, but believes the selloff is overdone "as no toxicity has been observed preclinically."
PRTK Paratek Pharmaceuticals
$3.51

0.31 (9.69%)

01/16/19
ADAM
01/16/19
NO CHANGE
Target $25
ADAM
Buy
Paratek Pharmaceuticals price target raised to $25 from $14 at Canaccord
Canaccord analyst Dewy Steadman raised his price target on Paratek Pharmaceuticals to $25 from $14 following meetings with management. The analyst came away encouraged that the story sets up well with reasonable expectations for 2019. He also said the company's stretch goal of $500M in Nuzyra revenue by 2024 is positively surprising and potentially achievable, but remains out of his estimates for now. Steadman reiterated his Buy rating on Paratek Pharmaceuticals shares.
03/12/19
ADAM
03/12/19
NO CHANGE
Target $25
ADAM
Buy
Canaccord continues to see attractive entry point for Paratek
Canaccord analyst Dewey Steadman maintained a Buy rating and $25 price target on Paratek Pharmaceuticals following the release of the company's 10-K. In a research note to investors, Steadman says he is "encouraged" by the company's initial marketing efforts for Nuzyra and sees initial revenue guidance of $10M-$13M as achievable. As Nuzyra gains market acceptance over the coming quarters, Steadman says he likes the Paratek story and continues to see an attractive entry point for what could be one of the most compelling true antibacterial product launches in the past several years;
03/18/19
ADAM
03/18/19
NO CHANGE
ADAM
Paratek CFO departure not concerning, says Canaccord
Canaccord analyst Dewey Steadman maintained a Buy rating and $25 price target on Paratek Pharmaceuticals, saying he is not concerned by the departure of CFO Doug Pagan as he left the company "in good shape." Steadman continues to see an "attractive entry point for what could be one of the most compelling true antibacterial product launches in the past several years" in Nuzyra.
05/09/19
WEDB
05/09/19
NO CHANGE
Target $12
WEDB
Outperform
Paratek Pharmaceuticals price target lowered to $12 from $17 at Wedbush
Wedbush analyst Robert Driscoll lowered his price target for Paratek Pharmaceuticals to $12 from $17 following quarterly results. The analyst sees a measured launch ahead for Nuzyra, with momentum continuing toward an "ultimately successful" commercial launch of a differentiated antibiotic. He reiterates an Outperform rating on the shares.
OCX OncoCyte
$1.62

-0.045 (-2.70%)

06/27/19
BNCH
06/27/19
NO CHANGE
Target $7
BNCH
Buy
OncoCyte reaction to DetermaVu delay overdone, says Benchmark
Benchmark analyst Bruce Jackson said that he views yesterday's price action in shares of OncoCyte after the company announced that it needs additional time to complete the CLIA validation study as overdone. The validation process could be converted to an automated one, said the company, which Jackson would view as a positive since it tends to improve overall test performance by removing a source of variability. Jackson, who said he doesn't view the announcement of the delay for the DetermaVu test as a major setback for OncoCyte, sees the associated pullback as a buying opportunity and keeps a Buy rating and $7 price target on the shares.
07/03/19
BNCH
07/03/19
NO CHANGE
BNCH
Speculative Buy
BioTime sale of OncoCyte shares expands shareholder base, says Benchmark
Benchmark analyst Bruce Jackson noted that OncoCyte's (OCX) majority shareholder, BioTime (BTX), is selling 2.25M of its 14.7M shares in the former. He views the share sale as positive for both, noting that BioTime will gain additional capital and OncoCyte will gain a broader shareholder base. BioTime will still hold about 24% of OncoCyte's stock following the deal's completion and Broadwood Partners will be building on its 15.6% stake by acquiring about 1M of the 2.25M shares being offered, noted Jackson, who keeps a Speculative Buy rating on OncoCyte shares.
08/15/19
PIPR
08/15/19
NO CHANGE
PIPR
OncoCyte delayed DetermaVu study by 6-9 months, says Piper Jaffray
OncoCyte management said last night that the CLIA Validation study for DetermaVu will be delayed 6-9 months from now following inconsistencies with the RNA extraction reagents used in the workflow, which was impacting reproducibility of the data, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst pushed out his assumptions for reimbursement and commercialization by six months and lowered his price target for the shares to $5.40 from $6. His new model assumes commercialization in Q3 of 2020 and reimbursement beginning in Q3 of 2021. Quirk keeps an Overweight rating on he shares.
09/05/19
PIPR
09/05/19
NO CHANGE
PIPR
OncoCyte acquisition of Razor Genomics stake 'smart,' says Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating and $5.40 price target on OncoCyte after the company announced it was acquiring a 25% stake in Razor Genomics for $10M, with an option to buy the entire company for a value of around $33M, which Quirk called a "smart deal... consistent with OncoCyte's long-term view of menu expansion." Additionally, the analyst was positive as OncoCyte reiterated it was close to restarting the CLIA Clinical Validation process for DetermaVu.
NVS Novartis
$86.83

0.28 (0.32%)

09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Europe 1 List changes at BofA/Merrill
BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.
NUAN Nuance
$15.44

-0.21 (-1.34%)

01/15/19
01/15/19
DOWNGRADE
Target $17

Equal Weight
Morgan Stanley downgrades Nuance to Equal Weight on lack of near-term catalysts
As previously reported, Morgan Stanley analyst Sanjit Singh downgraded Nuance to Equal Weight from Overweight, stating that he sees the potential for growth to accelerate in FY20 but he also sees a lack of near term catalysts along with tougher comps in healthcare. Singh lowered his price target on Nuance shares to $17 from $19.
09/27/19
WEDB
09/27/19
INITIATION
Target $23
WEDB
Outperform
Cerence initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated Cerence (CRNC) with an Outperform rating and $23 price target. On September 16, Nuance Communications (NUAN) announced that, in connection with the previously announced spin-off of Cerence, it has been advised by Nasdaq that shares of Cerence common stock begin trading on a "when-issued" basis on the Nasdaq Global Select Market under the symbol "CRNCV" and will continue through October 1. Following the distribution date, shares of Cerence common stock are expected to trade "regular-way," at which time Cerence common stock will trade under the symbol "CRNC" on the Nasdaq Global Select Market.
10/01/19
RAJA
10/01/19
INITIATION
Target $38
RAJA
Strong Buy
Cerence initiated with a Strong Buy at Raymond James
Raymond James analyst Brian Gesuale initiated Cerence (CRNC) with a Strong Buy rating and a $38 price target. The analyst said that "Cerence is an artificial intelligence based natural language digital assistant in the automobile that unlocks a broader content ecosystem, enabling a safer more enjoyable customer experience. Think of this as the 'Siri' or 'Alexa' of the car." Gesuale said that the market is valuing Cerence as a high-end auto supplier, but he believes that will go up as more becomes known about the story. As previously reported, Nuance Communications (NUAN) is spinning off Cerence.
10/02/19
EVER
10/02/19
INITIATION
Target $24
EVER
Outperform
Cerence initiated with an Outperform at Evercore ISI
Evercore ISI analyst Chris McNally initiated coverage of Cerence (CRNC), which was just spun out of Nuance (NUAN), with an Outperform rating and $24 price target. He sees a mid-teens compound annual growth rate for the Automotive Voice/Cognitive Assistance industry through 2025, noting that Cerence has a "dominant 75%+" market share.
MYL Mylan
$18.31

0.16 (0.88%)

09/19/19
JPMS
09/19/19
NO CHANGE
Target $37
JPMS
Neutral
Pfizer price target lowered to $37 from $46 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Pfizer (PFE) to $37 from $46 and keeps a Neutral rating on the shares. While the Mylan (MYL)/Upjohn transaction creates a smaller, innovation-driven biopharma business and increases the company's near-term growth prospects, Pfizer's multiple is ahead of itself with the remaining company trading near the top end of the major pharma valuation range, Schott tells investors in a research note. He points out that Pfizer is facing "another major patent cycle" post 2025.
09/24/19
CANT
09/24/19
NO CHANGE
CANT
Mylan, Perrigo, Zoetis unlikely to be hurt by headline risks, says Cantor
Cantor Fitzgerald analyst Louise Chen does not think investors are "ready to embrace healthcare yet" ahead of potential legislative changes to drug pricing and an election year where healthcare is a major topic of debate. With that said, she thinks the business models for Mylan (MYL), Perrigo (PRGO) and Zoetis (ZTS) are not likely to be impacted by the headline risks in healthcare.
10/16/19
MSCO
10/16/19
NO CHANGE
Target $212
MSCO
Underweight
Biogen deadline to settle Tecfidera IPR challenge nearing, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that the USPTO's Patent Trial and Appeal Board will hold an oral hearing on November 13 for an IPR challenge of the only patent that protects Biogen's (BIIB) Tecfidera beyond 2020, after which he believes it will be hard for Biogen to settle out of this case. With that view in mind, he can see a scenario where Biogen reaches a settlement with both Mylan (MYL) and Sawai with a launch date before 2024, in which case he would foresee 1%-5% downside for Biogen shares. In a scenario where Biogen settles with launch date of 2024 or later, Harrison could see 5%-15% upside for Biogen shares. In a scenario where the oral hearing passes without a settlement, the analyst could see 1%-10% downside for Biogen shares. His base case expectation is that Biogen is unlikely to settle the IPR before the hearing, noted Harrison, who keeps an Underweight rating and $212 price target on Biogen shares.
MRK Merck
$81.30

-3.24 (-3.83%)

10/10/19
JPMS
10/10/19
NO CHANGE
Target $96
JPMS
Overweight
JPMorgan analysis indicates 'highly inexpensive valuation' for Merck
Investor sentiment on Merck shares remains positive but relative valuation and Keytruda concentration remains the primary pushback on the thesis, JPMorgan analyst Chris Schott tells investors in a research note. However, the analyst's sum-of-the-parts valuation analysis indicates a "highly inexpensive valuation" when incorporating a premium for the company's Animal health and Vaccines franchises. Further, while Keytruda represents a sizable portion of Merck's earnings and growth, the company has a full decade to further develop its pipeline and next-generation product offerings before the product faces biosimilar competition, Schott contends. As such, he continues to see Merck as one of the best positioned names in his coverage group. The analyst keeps an Overweight rating on the shares with a $96 price target.
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Neutral
Merck reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Merck with a Neutral rating and $90 price target. The analyst said he has a conservative near-term outlook on Merck as he sees "limited higher-impact events driving further positive sentiment."
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
MNK Mallinckrodt
$2.86

0.32 (12.60%)

09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
MLNT Melinta Therapeutics
$4.84

0.265 (5.80%)

06/20/19
WBBS
06/20/19
DOWNGRADE
Target $8
WBBS
Hold
Melinta Therapeutics downgraded to Hold from Speculative Buy at WBB Securities
WBB Securities downgraded Melinta Therapeutics to Hold from Speculative Buy with an $8 price target after the stock rose 224% yesterday to $6.41.
06/20/19
HCWC
06/20/19
NO CHANGE
Target $13
HCWC
Buy
Melinta rally reflects 'deeply oversold situation,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes yesterday's 224% rally in shares of Melinta Therapeutics reflects a "deeply oversold situation, more than anything else." With that said, the analyst views the FDA's acceptance of Melinta's supplemental New Drug Application of Baxdela as "clearly positive news and an important milestone." To reflect the impact of the company's ongoing cost restructuring, Arce lowered his price target for the shares to $13 from $45. He affirms a Buy rating on Melinta Therapeutics.
06/20/19
GABE
06/20/19
NO CHANGE
GABE
Gabelli fears Melinta Therapeutics may declare bankruptcy
Gabelli analyst Kevin Kedra kept a Sell rating on Melinta Therapeutics. He recommended investors sell the name after Wednesday's news that the FDA had accepted the sNDA filing for Baxdela, which caused Melinta shares to rise over 220%, which Kedra called a "baffling stock move." He sees near-term cash concerns for the company, which ended Q1 with $117M in cash and $223M of debt, along with operating cash burn of about $20M in the quarter, and fears the company could be forced to declare bankruptcy.
08/12/19
HCWC
08/12/19
DOWNGRADE
HCWC
Neutral
Melinta Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Melinta Therapeutics to Neutral from Buy without a price target. The company on Friday issued a surprise announcement that both Chairman Kevin Ferro and CEO John Johnson had voluntarily resigned from their respective positions, and the board, Arce tells investors in a research note. This marks Melinta's fourth CEO departure in as many years, says the analyst. He cites a "high degree of uncertainty and instability" with Melinta in the near term for his downgrade.
MDT Medtronic
$104.52

-2.11 (-1.98%)

09/16/19
JPMS
09/16/19
NO CHANGE
JPMS
Overweight
Medtronic one of the few that could see multiple expansion, says JPMorgan
JPMorgan analyst Robbie Marcus believes Medtronic's pipeline is "deep and often overlooked." He sees a number of "significant potential catalysts" over the coming year that he believes many investors aren't focused on. The analyst thinks investors will want to own Medtronic not only for the expected sales acceleration, from ~4% this fiscal year to ~5% in fiscal 2021, but also for the potential upside in the out-years as pipeline catalysts, that "aren't appropriately modeled by the Street," play out. Medtronic is one of the few large-cap names that could see further multiple expansion, says Marcus, who reiterates an Overweight rating on the shares.
09/27/19
PIPR
09/27/19
NO CHANGE
PIPR
Piper says insulin pump survey most positive for Insulet
Piper Jaffray analyst JP McKim conducted an insulin delivery survey in August and found that pump penetration is going "much higher" both in type 1s and in type 2s. The growth in the type 2 market is underappreciated by investors and will largely benefit Insulet (PODD) today given the pharmacy channel increases that access, McKim tells investors in a research note. Further, survey indicated that Medtronic (MDT) is expected to lose between 1,100-1,300 basis points of market share with Tandem Diabetes (TNDM) being the greatest beneficiary with the biggest uptick forecast in 2020, says the analyst. McKim views the insulin pump survey as most positive for Insulet.
LJPC La Jolla
$8.41

-0.24 (-2.77%)

01/23/19
JPMS
01/23/19
UPGRADE
Target $9
JPMS
Neutral
La Jolla upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Anupam Rama upgraded La Jolla Pharmaceutical to Neutral while lowering his price target for the shares to $9 from $18. The analyst made a host of rating changes in the smid cap Biotech space following his firm's Healthcare Conference.
01/23/19
JPMS
01/23/19
UPGRADE
Target $9
JPMS
Neutral
JPMorgan sees La Jolla as range bound, upgrades shares to Neutral
JPMorgan analyst Anupam Rama upgraded La Jolla Pharmaceutical to Neutral from Underweight while cutting his price target for the shares to $9 from $18. The analyst expects the focus to shift away from the Giapreza U.S. launch to other clinical programs, in particular the LJPC-401 program. He believes the shares shares will be more range bound in the first half of 2019, which forms his Neutral rating.
06/06/19
HCWC
06/06/19
NO CHANGE
HCWC
La Jolla price target raised to $27 from $25 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for La Jolla Pharmaceutical to $27 from $25 after the company announced positive data from its pre-specified interim analysis of the Phase 2 clinical study evaluating LJPC-401 in patients with hereditary hemochromatosis. The analyst increased his probability of success for LJPC-401 to 35% from 30% following the data and keeps a Buy rating on La Jolla shares.
06/07/19
RHCO
06/07/19
NO CHANGE
Target $20
RHCO
Buy
La Jolla opportunity for '401 to be expanded with HH patients, says SunTrust
SunTrust analyst Joon Lee kept his Buy rating and $20 price target on La Jolla, saying the stock price remains undervalued despite the 92% rally yesterday on the news that its phase 2 LJPC-401 study in hereditary hemochromatosis, or HH, resulted in "statistic significance". The analyst notes that some 640K - 1.6M HH patients exist in in the U.S., and given '401's superior efficacy and tolerability, its pricing may come at a premium relative to the $15K/year option for Exjade. Lee adds that the market assessment of HH prevalence is clouded by the tendency for the disease to be "under-diagnosed".
SIEGY Siemens
$0.00

(0.00%)

09/04/19
DBAB
09/04/19
UPGRADE
DBAB
Buy
Siemens upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Siemens to Buy from Hold with a price target of 105 euros.
09/25/19
HSBC
09/25/19
UPGRADE
HSBC
Buy
Siemens upgraded to Buy from Hold at HSBC
HSBC analyst Michael Hagmann upgraded Siemens to Buy from Hold and raised his price target for the shares to 120 euros from 114 euros.
09/25/19
HSBC
09/25/19
UPGRADE
HSBC
Buy
HSBC upgrades Siemens to Buy on potential 'Vision 2020+' changes
HSBC analyst Michael Hagmann upgraded Siemens to Buy from Hold and raised his price target for the shares to 120 euros from 114 euros. With its "Vision 2020+," the analyst believes that before the end of the next decade, Siemens will largely consist of the constituents of Digital Industries, Smart Infrastructure and IIoT related activities such as Mindsphere & Digital Services as well as Siemens Integration Services and separately listed Siemens Healthineers. The Powerhouse and Mobility will just like Infineon become completely separate companies over time, Hagmann tells investors in a research note. He sees the Powerhouse spinoff as creating a "more focused group and an important medium-term catalyst."
09/25/19
09/25/19
UPGRADE

Fly Intel: Top analyst upgrades
Catch up on today's top analyst upgrades with this list compiled by The Fly: 1. Berry Global (BERY) upgraded to Buy on valuation at BofA/Merrill with analyst George Staphos saying he thinks the shares now reflect "a pessimistic, mid-single digit perpetuity decline rate" and concerns on plastics that have been a headwind for sector multiples. 2. Toll Brothers (TOL), Lennar (LEN), and KB Home (KBH) upgraded to Outperform from Market Perform at Raymond James. 3. BancorpSouth (BXS) upgraded to Buy from Hold at SunTrust with analyst Jennifer Demba saying she is positive on the company's "steady" small bank acquisition strategy and its "less asset sensitive" balance sheet, adding that its large mortgage and insurance business help to offset the interest rate related challenges in spread income. 4. Siemens (SIEGY) upgraded to Buy from Hold at HSBC with analyst Michael Hagmann saying with its "Vision 2020+," he believes that before the end of the next decade, Siemens will largely consist of the constituents of Digital Industries, Smart Infrastructure and IIoT related activities such as Mindsphere & Digital Services as well as Siemens Integration Services and separately listed Siemens Healthineers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$45.31

-0.64 (-1.39%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
TAK Takeda Pharmaceutical
$17.55

0.03 (0.17%)

05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
08/15/19
DAIW
08/15/19
DOWNGRADE
DAIW
Neutral
Takeda Pharmaceutical downgraded to Neutral from Outperform at Daiwa
Daiwa analyst Kazuaki Hashiguchi downgraded Takeda Pharmaceutical to Neutral from Outperform with a price target of 3,700 yen, down from 4,500 yen.
09/05/19
HCWC
09/05/19
NO CHANGE
HCWC
Buy
H.C. Wainwright says KemPharm may have picked 'best possible' partner in GPC
After KemPharm (KMPH) announced a deal with private equity firm Gurnet Point Capital, H.C. Wainwright analyst Oren Livnat noted that investors reacted negatively to the deal, which he thinks is likely due to the relatively small $10M up-front and the partner being an unknown rather than an obvious ADHD player such as Takeda's (TAK) Shire. However, he thinks the Street is "entirely missing" that GPC "may actually be the best possible partner" given that it previously acquired CNS-focused Corium International and recently put new leadership in place almost entirely made up of recent Shire senior management. Livnat also believes that "deep-pocketed, private" GPC may be more willing than any other player, including Takeda, to provide the needed commercial support to make KP415 a success, he tells investors. He maintains a $3 price target and Buy rating on KemPharm shares.
09/24/19
JEFF
09/24/19
INITIATION
JEFF
Buy
Takeda Pharmaceutical initiated with a Buy at Jefferies
Jefferies analyst Stephen Barker started Takeda Pharmaceutical with a Buy rating and 6,000 yen price target.
UTHR United Therapeutics
$84.18

0.13 (0.15%)

07/01/19
07/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anaplan (PLAN) upgraded to Buy from Neutral at Goldman Sachs with analyst Heather Bellini saying the company's deal sizes are growing and the pace of its expansions are increasing as sales productivity improves. 2. Six Flags (SIX) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress citing an improving near-term setup, led by his Key First Look data supporting above-consensus attendance trends for Q2, meaningfully easier Q3 weather compares, and a de-risked international scenario, all against what he believes is a rock-bottom level of sentiment around the name. 3. Western Digital (WDC) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying he believes the Huawei ban has been a "major overhang" for handset radio frequency suppliers Qorvo (QRVO) and Skyworks (SWKS), and memory suppliers like Western Digital. 4. Valvoline (VVV) upgraded to Buy from Neutral at Buckingham. 5. United Therapeutics (UTHR) upgraded to Outperform from Neutral at Credit Suisse with analyst Martin Auster saying he sees downside as limited with multiple attributes that could support near-term stabilization/rebound, including potential for less aggressive generic uptake, greater recognition of steady Tyvaso/Orenitram cash flows with potential for strong Tyvaso tail value, ralinepag's potential best-in-class profile, potential for share buybacks, and potential for activism/M&A. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/19
JEFF
08/01/19
UPGRADE
Target $90
JEFF
Hold
United Therapeutics upgraded to Hold from Underperform at Jefferies
Jefferies analyst Eun Yang upgraded United Therapeutics to Hold from Underperform with an unchanged price target of $90. The analyst cites valuation for the upgrade after the company reported higher Q2 revenue and lower operating expenses.
08/01/19
LTCO
08/01/19
UPGRADE
Target $106
LTCO
Buy
United Therapeutics upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan upgraded United Therapeutics to Buy from Neutral and raised his price target for the shares to $106 from $103. The analyst is encouraged by the product sales reported by the company in Q2. He expects United Therapeutics to continue to maintain a "significant" market share in pulmonary hypertension with Remodulin due to practitioner preference. The company will be able to maintain a "relatively steady" revenue base and potentially continue to grow revenues as its pipeline advances to replace their genericized products, Kaplan tells investors in a research note.
08/01/19
08/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Spotify (SPOT) upgraded to Hold from Sell at Loop Capital with analyst Alan Gould saying the company's Q2 marked "another good quarter" as it reached renewal deals with 2 of 4 major labels for global recording. 2. Crown Castle (CCI) upgraded to Overweight from Neutral at JPMorgan. 3. Vanda Pharmaceuticals (VNDA) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying the current stock price is undervaluing Vanda's "profitable" base business due to "very poor" investor sentiment related to pipeline agent tradipitant. 4. United Therapeutics (UTHR) upgraded to Hold from Underperform at Jefferies with analyst Eun Yang citing valuation. 5. Five9 (FIVN) upgraded to Overweight from Neutral at JPMorgan and to Buy from Neutral at Dougherty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VCYT Veracyte
$26.17

-0.01 (-0.04%)

07/02/19
NEED
07/02/19
INITIATION
Target $33
NEED
Buy
Veracyte initiated with a Buy at Needham
Needham analyst Stephen Unger started Veracyte with a Buy rating and $33 price target. The company has "significant potential for meaningful" long-term revenue growth as its advanced diagnostic tests that improve patient outcomes, while also reducing diagnostic costs, commercializes, Unger tells investors in a research note. The analyst believes Veracyte's Afirma Gene Expression Classifier is a well established test used by U.S. physicians to improve the diagnosis of thyroid nodules.
07/02/19
07/02/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veru (VERU) initiated with an Overweight at Cantor Fitzgerald. 2. Uber (UBER) initiated with a Hold at Stifel. 3. Wyndham Hotels & Resorts (WH) initiated with an Overweight at Barclays. 4. Veracyte (VCYT) initiated with a Buy at Needham. 5. Paysign (PAYS) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/19
LSCM
07/31/19
INITIATION
Target $35
LSCM
Buy
Veracyte initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten started Veracyte with a Buy rating and $35 price target. Veracyte can expand its offering to improve decision-making across the patient care continuum by leveraging its technology and bioinformatics platforms to develop and commercialize new product offerings, Flaten tells investors in a research note. He believes the company's late 2019 nasal swab test data for lung cancer "could further validate this evolution."
07/31/19
07/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verra Mobility (VRRM) initiated with a Neutral at Goldman Sachs. 2. Myomo (MYO) initiated with a Buy at Ascendiant. 3. Chiasma (CHMA) initiated with an Overweight at Piper Jaffray. 4. IAA (IAA) initiated with a Buy at Jefferies. 5. Veracyte (VCYT) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WTKWY Wolters Kluwer
$0.00

(0.00%)

05/17/19
JPMS
05/17/19
DOWNGRADE
JPMS
Underweight
Wolters Kluwer downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Daniel Kerven downgraded Wolters Kluwer to Underweight from Neutral with a price target of 57 euros.

TODAY'S FREE FLY STORIES

BRMK

Broadmark Realty Capital

$10.94

-0.02 (-0.18%)

07:40
11/22/19
11/22
07:40
11/22/19
07:40
Initiation
Broadmark Realty Capital initiated  »

Broadmark Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/22/19
11/22
07:40
11/22/19
07:40
General news
Treasury Market Outlook: bond yields are modestly richer outside of Asia »

Treasury Market Outlook:…

NKSH

National Bankshares

$47.08

1.59 (3.50%)

07:39
11/22/19
11/22
07:39
11/22/19
07:39
Downgrade
National Bankshares rating change  »

National Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$2.03

0.01 (0.50%)

07:37
11/22/19
11/22
07:37
11/22/19
07:37
Initiation
Precipio initiated  »

Precipio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$288.66

3.68 (1.29%)

07:36
11/22/19
11/22
07:36
11/22/19
07:36
Hot Stocks
Biogen announces results from Phase 3 EVOLVE-MS-2 study »

Biogen announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

APDN

Applied DNA Sciences

$4.14

(0.00%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Upgrade
Applied DNA Sciences rating change  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$126.80

-0.04 (-0.03%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

LYFT

Lyft

$46.77

2.92 (6.66%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

ZM

Zoom Video

$69.91

-1.02 (-1.44%)

07:34
11/22/19
11/22
07:34
11/22/19
07:34
Initiation
Zoom Video initiated  »

Guggenheim starts Zoom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

, F

Ford

$8.72

-0.005 (-0.06%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Recommendations
Tesla, Ford, General Motors analyst commentary  »

Tesla's $39,900…

TSLA

Tesla

F

Ford

$8.72

-0.005 (-0.06%)

GM

General Motors

$34.66

-0.6 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

  • 04

    Feb

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$29.51

0.52 (1.79%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Upgrade
HMS Holdings rating change  »

Guggenheim upgrades HMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:31
11/22/19
11/22
07:31
11/22/19
07:31
Earnings
Auxly Cannabis reports Q3 EPS (C$0.03) vs. (C$0.02) last year »

Reports Q3 revenue C$1.6M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$85.30

-0.41 (-0.48%)

07:30
11/22/19
11/22
07:30
11/22/19
07:30
Hot Stocks
Anixter, CD&R announce amendment to up merger consideration to $82.50 per share »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:28
11/22/19
11/22
07:28
11/22/19
07:28
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$52.46

-1.9 (-3.50%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Recommendations
Emergent BioSolutions analyst commentary  »

Cantor reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$47.17

1.2 (2.61%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Periodicals
Sanofi EVP in charge of strategy leaving by end of month, Reuters says »

Muzammil Mansuri,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NXRT

NexPoint Residential

$47.61

-0.49 (-1.02%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Initiation
NexPoint Residential initiated  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$28.49

-0.15 (-0.52%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Initiation
Apellis initiated  »

Apellis has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KKR

KKR

$29.07

-0.25 (-0.85%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Periodicals
KKR gets halfway in $3B Asia infrastructure fundraising, Reuters says »

According to Reuters, KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.70

-0.21 (-3.55%)

07:25
11/22/19
11/22
07:25
11/22/19
07:25
Conference/Events
RedHill Biopharma to host investor & analyst day »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

BXRX

Baudax Bio

$4.66

-0.59 (-11.24%)

07:24
11/22/19
11/22
07:24
11/22/19
07:24
Initiation
Baudax Bio initiated  »

Baudax Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.84

0.455 (0.81%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Bristol-Myers initiated  »

Bristol-Myers resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.